Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
This is the company’s second FDA orphan drug designation with ketamine. Seeking to enter Phase 2 clinical trials in 2022.
Ketamine One Launching Two Inaugural Research Studies
The single-arm studies will be focused on Treatment-Resistant Depression and Post-Traumatic Stress Disorder.
Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF
The company announced its inclusion in the actively-traded AdvisorShares Psychedelics ETF currently trading under the ticker symbol “PSIL” on the NYSE Arca exchange.
Clearmind Medicine Appoints New Members to Its Scientific Advisory Board
The company announces that professors Wim van den Brink and Gabriele Fischer have joined the Company’s scientific advisory board.
MindMed Joins Clinical Trials Transformation Initiative
MindMed has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Algernon has filed a scientific advice meeting request with the United Kingdom (“UK”) Medicines and Healthcare Products Regulatory Agency (“MHRA”) for a Phase 1/2a stroke study with AP-188 (“N,N-dimethyltryptamine” or “DMT”).
Want to catch up on more industry news? See last week’s news update here.